

# A Validated Integration Of Tumor Deposits In N Staging For Prognostication In Colon Cancer

Richard Sassun M.D.<sup>1</sup>, Annaclara Sileo M.D.<sup>1</sup>, Jyi Cheng Ng M.D.<sup>1</sup>, Sara Aboelmaaty M.D.<sup>1</sup>, Ibrahim Gomaa M.D.<sup>1</sup>, Jay Mandrekar Ph.D.<sup>2</sup>, Kristen K. Rumer M.D., M.S.<sup>1</sup>, Nicholas P. McKenna M.D., M.S.<sup>1</sup>, David W. Larson M.D., M.B.A.<sup>1</sup>

<sup>1</sup>Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.

<sup>2</sup>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

## ABSTRACT

**Background:** Tumor deposits (TD) have prognostic value in colon cancer (CC), but the current AJCC staging only consider them if there are no concurrent positive lymph nodes (LN<sup>+</sup>). This study aimed to devise a staging system for CC, merging TD with LN<sup>+</sup> count while retaining the current AJCC staging framework.

**Methods:** A “real LN<sup>+</sup> (RLN<sup>+</sup>)” count was derived using a two-criteria formula: if TD=0, the AJCC N staging applies; if TD=1 and LN<sup>+</sup>=0, then RLN<sup>+</sup>=4 since the N1c stage has an overall survival (OS) similar to N2a stage. RLN<sup>+</sup> was used to derive Sassun-Mayo N/TNM stages according to AJCC staging. ROC and Kaplan-Meier analyses were performed using the two stagings, assessing their efficiency for 3-year OS. External validation was performed using the National Cancer Database (NCDB 2010-2021).

**Results:** 788 institutional patients with stage III CC (2010-2022) were included. ROC curve areas were improved using the Sassun-Mayo stages (3-year death: 0.63 AJCC TNM; 0.66 Sassun-Mayo TNM). Kaplan-Meier curves revealed visible overlaps among AJCC N stages, which were absent in the Sassun-Mayo N stages. NCDB validation on 77,790 patients was successful yielding a significantly higher concordance index in the Sassun-Mayo N/TNM stages. Patients upstaged from N1 to N2 (13.2%) had a 3-year OS identical to AJCC N2a patients. Additionally, 3.9% of patients were upstaged from N2a to N2b.

**Conclusions:** 17.1% of stage III CC patients were understaged. The Sassun-Mayo N/TNM stages provided superior OS stratification compared to the current AJCC staging, suggesting that their implementation would improve the prognostication in CC.

# Figures

**Figure 1. Survival curves for different staging systems.**

Red-circled indicates incorrect stratification.

(A) Kaplan-Meier survival curves for 3 years overall survival according to AJCC N stages; (B) Kaplan-Meier survival curves for 3 years overall survival according to the Sassun-Mayo N stages; (C) Inclusion of patients with TD<sup>+</sup> in AJCC N1a and N1b stages overestimates their prognosis. Conversely, the prognosis for AJCC N1a/b patients that are TD<sup>-</sup> is artificially lowered by the inclusion of patients with tumor deposits in those groups; (D) The overall survival for these two groups was nearly identical (87% at 3 years).

